*NOTE: the brochure was already reviewed by an editor*
Idiopathic pulmonary fibrosis (IPF) is a type of lung disease characterized by the thickening and stiffening of tissues in the lungs. While the prognosis for patients diagnosed with IPF is poor (survival of three to five years after diagnosis, in most cases), various therapies can relieve symptoms, prevent further lung scarring, and improve patients’ quality of life. Different drug classes are used to target the respective physiological mechanisms. Tyrosine kinase inhibitors (nintedanib [Boehringer Ingelheim’s Ofev]), for example, blocks the action of enzymes that cause fibrosis, while antifibrotic agents such as pirfenidone (Roche / Genentech’s Esbriet) reduce lung fibrosis by downregulating growth factor production. This analysis of patient-level claims data provides insights into the dynamics of the IPF treatment landscape.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
Markets covered: United States
Key drugs: Azathioprine, benralizumab, nintedanib, pirfenidone, sildenafil
added by Sabah on Mar 28